Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.

ABSTRACT:

Aims

Obesity increases the risk of heart failure with preserved (HFpEF), but not reduced ejection fraction (HFrEF). The glucagon-like peptide-1 receptor agonist (GLP-1-RA) semaglutide improves outcome of patients with obesity with or without HFpEF, while GLP-1-RAs were associated with adverse outcome in patients with HFrEF. Here, we investigate the effect of in vivo treatment with semaglutide on excitation-contraction coupling in a rat model of obesity.

Methods and results

Rats received high-fat/high-fructose diet for 8 weeks and were then randomized to semaglutide (HFD/Sema) or vehicle (HFD/Veh) for another 8 weeks, during which they could choose between HFD and a low-fat/high-fructose diet (LFD). Control rats received either standard chow (CON), HFD or LFD only, without tr

SUBMITTER: Sequeira V 

PROVIDER: S-EPMC11911617 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature